Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Cash from Financing Activities (2020 - 2025)

HCW Biologics (HCWB) has disclosed Cash from Financing Activities for 6 consecutive years, with $1.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Financing Activities fell 32.23% year-over-year to $1.9 million, compared with a TTM value of $13.1 million through Sep 2025, up 46.53%, and an annual FY2024 reading of $15.6 million, up 107217.9% over the prior year.
  • Cash from Financing Activities was $1.9 million for Q3 2025 at HCW Biologics, down from $4.6 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $98.5 million in Q4 2021 and bottomed at -$48.4 million in Q3 2021.
  • Average Cash from Financing Activities over 5 years is $4.1 million, with a median of $6000.0 recorded in 2022.
  • The sharpest move saw Cash from Financing Activities tumbled 883.93% in 2021, then soared 222022.78% in 2024.
  • Year by year, Cash from Financing Activities stood at $98.5 million in 2021, then plummeted by 100.04% to -$39846.0 in 2022, then soared by 61.73% to -$15250.0 in 2023, then soared by 43540.29% to $6.6 million in 2024, then plummeted by 71.35% to $1.9 million in 2025.
  • Business Quant data shows Cash from Financing Activities for HCWB at $1.9 million in Q3 2025, $4.6 million in Q2 2025, and -$53103.0 in Q1 2025.